scholarly journals Risk factors for relapse in relapsing remitting multiple sclerosis

2021 ◽  
Vol 17 (Sup1) ◽  
pp. S34-S36
Author(s):  
James Hill ◽  
Joanna Harrison ◽  
Karen Palmer
Keyword(s):  
Risk Factors ◽  
Multiple Sclerosis ◽  
Common Type ◽  
Previous Evidence ◽  
Factors Associated ◽  
Multiple Factors ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Risk Of Relapse

Relapsing remitting is the most common type of multiple sclerosis, affecting approximately 85% of all patients. Previous evidence has suggested that the risk factors for developing relapsing remitting multiple sclerosis is multifactorial. Similarly, it has been suggested that these factors also influence the risk of relapse. This article critically appraises and evaluates a systematic review that examined multiple factors associated with the risk of relapse for relapsing remitting multiple sclerosis.

Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

2019 ◽  
Vol 267 (1) ◽  
pp. 125-131 ◽  
Author(s):  
Fabian Sierra Morales ◽  
Igor J. Koralnik ◽  
Shiva Gautam ◽  
Soleil Samaan ◽  
Jacob A. Sloane
Keyword(s):  
Risk Factors ◽  
Multiple Sclerosis ◽  
Dimethyl Fumarate ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis

2017 ◽  
Vol 24 (7) ◽  
pp. 991-994 ◽  
Author(s):  
Ingrid Meinl ◽  
Joachim Havla ◽  
Reinhard Hohlfeld ◽  
Tania Kümpfel
Keyword(s):  
Multiple Sclerosis ◽  
At Risk ◽  
Disease Activity ◽  
Effective Treatment ◽  
Disease Course ◽  
Risk Of Recurrence ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Risk Of Relapse

Background: Fingolimod is an effective treatment for active relapsing–remitting multiple sclerosis (MS). Discontinuation of therapy may be followed by recurrence of disease activity. Thus, female MS patients may be at risk of relapse during pregnancy after stopping fingolimod. Objectives and methods: To report the disease course during pregnancy of five women who interrupted therapy with fingolimod for pregnancy. Results: All patients experienced relapses during pregnancy and/or postpartum after stopping fingolimod. Conclusion: The risk of recurrence of disease activity during pregnancy after stopping fingolimod may be substantial. This should be considered and discussed with MS patients who are planning to become pregnant.

scholarly journals Factors associated with relapses in relapsing-remitting multiple sclerosis

Medicine ◽  
2020 ◽  
Vol 99 (27) ◽  
pp. e20885
Author(s):  
Yao Xie ◽  
Ziyu Tian ◽  
Fang Han ◽  
Shibing Liang ◽  
Ying Gao ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Factors Associated ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document